TMEM219 and breast cancer: Consequent analysis of the survival effect of IGFBP-3 and TMEM219 in clinical subgroups of the breast cancer cohort revealed that clinical subgroup annotated as “histological type-Infiltrating Lobular Carcinoma” show marginally significant association of IGFBP-3 (FDR = 2.01∙10−1 (HR = 0.36)) and TMEM219 ((3.96∙10−2 (HR = 0.25)) with the survival outcome (Figure 10B,C).